Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nabriva appoints Dr David Chiswell as CEO

This article was originally published in Scrip

Executive Summary

The Austrian biotechnology company Nabriva Therapeutics has appointed Dr David Chiswell as its chief executive officer. He succeeds George Golumbeski, who has left the company. Dr Chiswell has been involved with Nabriva since its foundation, having served as chairman of the supervisory board for the past three years. He founded and led Cambridge Antibody Technology from 1990 until 2002 (including as its CEO from 1996-2002). Since leaving CAT, Dr Chiswell has served on the boards of a number of biotech companies, including Arakis, Arrow Therapeutics, Daniolabs and Sosei. He currently serves as chairman of Albireo Pharma, a position which he will retain. Nabriva was founded in February 2006 as a spin-out of Sandoz.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC001146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel